Skip to main navigation
Axsome Corporate Homepage
  • About Axsome
      About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
      Portfolio
    • All
    • Products Overview  down arrow
        Products Overview
      • All
      • Overview
      • Sunosi® (solriamfetol)
    • Pipeline Overview  down arrow
        Pipeline Overview
      • All
      • Overview
      • AXS-05
      • AXS-07
      • AXS-12
      • AXS-14
  • Conditions
      Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer’s
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Axsome Corporate Homepage
  • Science
      Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
      Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
      Careers
    • All
    • Overview
    • Current Opportunities

News Releases

News Releases

News Releases

News Releases Events

Keyword Search

March 1, 2023
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
NEW YORK , March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,
Read More
February 27, 2023
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Total fourth quarter net product sales of $24.4 million Auvelity ® launched October 19th , with fourth quarter net product sales of $5.2 million Sunosi ® fourth quarter net product sales of $19.2 million Sunosi ® license agreement for EU announced – $66 million upfront, potential milestones up to
Read More
February 22, 2023
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Axsome to receive an upfront payment of $66 million , and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics,
Read More
February 7, 2023
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
NEW YORK , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,
Read More
January 31, 2023
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET NEW YORK , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)
Read More
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Products Overview
    • Products Overview
    • Auvelity™ (dextromethorphan-bupropion)
    • Sunosi® (solriamfetol)
    • Pipeline Overview
    • AXS‑05
    • AXS‑07
    • AXS‑12
    • AXS‑14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer's
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Careers
    • Current Opportunities
Axsome
  • Contact Us
  • Privacy Notice
  • Terms of Use
  • See Axsome Therapeutics on Twitter
  • See Axsome Therapeutics on LinkedIn

© 2023 Axsome Therapeutics, Inc. All rights reserved. 22 Cortlandt St, 16th Floor, New York, NY 10007 info@axsome.com